<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1725</article-id><article-id pub-id-type="doi">10.15789/2220-7619-AOT-1725</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Analysis of the state of immunity in patients with chronic gastritis infected with <italic>Helicobacter pylori</italic></article-title><trans-title-group xml:lang="ru"><trans-title>Анализ состояния иммунитета у инфицированных <italic>Helicobacter pylori </italic> больных хроническим гастритом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9742-7646</contrib-id><name-alternatives><name xml:lang="en"><surname>Mokhonova</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Мохонова</surname><given-names>Екатерина Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Researcher, Immune Chemistry Laboratory, I.N. Blokhina Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology of the Rospotrebnadzor</p></bio><bio xml:lang="ru"><p>научный сотрудник лаборатории иммунохимии ФБУН Нижегородский НИИ эпидемиологии и микробиологии</p></bio><email>ekaterinamohonova@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5905-5722</contrib-id><name-alternatives><name xml:lang="en"><surname>Lapin</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Лапин</surname><given-names>В. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher, Immune Chemistry Laboratory</p></bio><bio xml:lang="ru"><p>младший научный сотрудник лаборатории иммунохимии</p></bio><email>fridens.95@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2441-6874</contrib-id><name-alternatives><name xml:lang="en"><surname>Melentiev</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Мелентьев</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher, Immune Chemistry Laboratory</p></bio><bio xml:lang="ru"><p>младший научный сотрудник лаборатории иммунохимии</p></bio><email>dim-melente@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7049-6935</contrib-id><name-alternatives><name xml:lang="en"><surname>Novikov</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Новиков</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Associate Professor, Leading Researcher, Immune Chemistry Laboratory</p></bio><bio xml:lang="ru"><p>к.б.н., доцент, ведущий научный сотрудник лаборатории иммунохимии</p></bio><email>novikov.dv75@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1394-3484</contrib-id><name-alternatives><name xml:lang="en"><surname>Neumoina</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Неумоина</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Medicine), Head Physician of the Infectious Diseases Clinic</p></bio><bio xml:lang="ru"><p>к.м.н., главный врач клиники инфекционных болезней</p></bio><email>tak1510@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6395-9014</contrib-id><name-alternatives><name xml:lang="en"><surname>Perfilova</surname><given-names>K. M.</given-names></name><name xml:lang="ru"><surname>Перфилова</surname><given-names>К. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Medicine), Deputy Head Physician of the Infectious Diseases Clinic</p></bio><bio xml:lang="ru"><p>к.м.н., заместитель главного врача клиники инфекционных болезней</p></bio><email>kperfilova@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0153-3573</contrib-id><name-alternatives><name xml:lang="en"><surname>Neumoina</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Неумоина</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Medicine), Head of the Department of Patient Consultation and Admission, Infectious Diseases Clinic</p></bio><bio xml:lang="ru"><p>к.м.н., зав. отделением консультации и приема больных клиники инфекционных болезней</p></bio><email>tak1510@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3724-4258</contrib-id><name-alternatives><name xml:lang="en"><surname>Troshina</surname><given-names>T. A.</given-names></name><name xml:lang="ru"><surname>Трошина</surname><given-names>Т. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Head of the Third Infection Diseases Department, Infectious Diseases Clinic</p></bio><bio xml:lang="ru"><p>зав. третьим инфекционным отделением клиники инфекционных болезней</p></bio><email>tak1510@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7073-9113</contrib-id><name-alternatives><name xml:lang="en"><surname>Shutova</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Шутова</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Medicine), Head of the Second Infection Diseases Department, Infectious Diseases Clinic</p></bio><bio xml:lang="ru"><p>к.м.н., зав. вторым инфекционным отделением клиники инфекционных болезней</p></bio><email>tak1510@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2449-7213</contrib-id><name-alternatives><name xml:lang="en"><surname>Novikov</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Новиков</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD (Biology), Professor, Head of the Immune Chemistry Laboratory</p></bio><bio xml:lang="ru"><p>д.б.н., профессор, зав. лабораторией иммунохимии</p></bio><email>mbre@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.N. Blokhina Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology of the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)</institution></aff><aff><institution xml:lang="ru">ФБУН Нижегородский НИИ эпидемиологии и микробиологии им. академика И.Н. Блохиной Роспотребнадзора</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2022-04-12" publication-format="electronic"><day>12</day><month>04</month><year>2022</year></pub-date><pub-date date-type="pub" iso-8601-date="2022-05-13" publication-format="electronic"><day>13</day><month>05</month><year>2022</year></pub-date><volume>12</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>306</fpage><lpage>314</lpage><history><date date-type="received" iso-8601-date="2021-04-19"><day>19</day><month>04</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-12-25"><day>25</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Mokhonova E.V., Lapin V.A., Melentiev D.A., Novikov D.V., Neumoina N.V., Perfilova K.M., Neumoina M.V., Troshina T.A., Shutova I.V., Novikov V.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Мохонова Е.В., Лапин В.А., Мелентьев Д.А., Новиков Д.В., Неумоина Н.В., Перфилова К.М., Неумоина М.В., Трошина Т.А., Шутова И.В., Новиков В.В.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Mokhonova E.V., Lapin V.A., Melentiev D.A., Novikov D.V., Neumoina N.V., Perfilova K.M., Neumoina M.V., Troshina T.A., Shutova I.V., Novikov V.V.</copyright-holder><copyright-holder xml:lang="ru">Мохонова Е.В., Лапин В.А., Мелентьев Д.А., Новиков Д.В., Неумоина Н.В., Перфилова К.М., Неумоина М.В., Трошина Т.А., Шутова И.В., Новиков В.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/1725">https://iimmun.ru/iimm/article/view/1725</self-uri><abstract xml:lang="en"><p><italic>Helicobacter pylori</italic> is considered an etiological agent of chronic gastritis and a number of other diseases of the gastrointestinal tract. The immune response to <italic>H. pylori</italic> is characterized by the development of both pro-inflammatory and tolerogenic reactions. Against this background, the possibility of forming autoimmune shifts is also assumed. The purpose of the present study was to conduct a comparative analysis of the state of immunity in patients with chronic gastritis in the exacerbation stage associated with and not associated with <italic>H. pylori</italic> infection. There were used whole peripheral blood (n = 50) and serum (n = 49) samples from 162 patients with primary chronic gastritis at the exacerbation stage, in which the presence or absence of <italic>H. pylori</italic> DNA was tested by real-time PCR in gastric juice. In the peripheral blood of patients, the relative content of CD4<sup>+</sup>FoxP3<sup>+</sup> cells (T regulators) and CD4<sup>+</sup>CD161<sup>+</sup> cells (IL-17 producing cells) was evaluated using flow cytofluorometry and monoclonal antibodies method, the level of mRNA FoxP3 and mRNA IL-17A was determined using real time RT-PCR, and the concentration of IL-2 and IL-23 was determined using enzyme immunoassay. It has been shown that in <italic>H. pylori</italic>-infected patients with chronic gastritis in the exacerbation stage in comparison with patients not infected with <italic>H. pylori</italic>, the content of CD4<sup>+</sup>FoxP3<sup>+</sup> cells, CD4<sup>+</sup>CD161<sup>+</sup> cells does not change in the blood, also with the level of mRNA FoxP3 and mRNA IL-17A. Since the equilibrium between the populations of Th17 cells and T regulators is modulated by IL-2, which is important for generating the population of T regulators, but inhibits polarization of the immune response towards Th17 cells, we conducted a comparative assessment of the serum IL-2 level in patients with chronic gastritis. All patients showed an increase in IL-2 content in comparison with the norm. In this case, the concentration of IL-2 in the blood of infected <italic>H. pylori</italic> patients was statistically significantly higher than in <italic>H. pylori</italic>-uninfected patients. An important regulator of the function of Th17 cells is also IL-23, which induces the differentiation of naive T lymphocytes into Th17 cells involved in inflammatory and autoimmune reactions. In this regard, we determined the level of this cytokine in the blood of patients with chronic gastritis. Multiple increase of IL-23 concentration in comparison with normal level and higher content of IL-23 in <italic>H. pylori</italic>-infected patients in comparison with uninfected patients were revealed. On the basis of the obtained data, it can be concluded that an increase in the concentration of IL-23 does not exclude the possibility of forming autoimmune shifts with its participation in persons with helicobacter infection, but the issue requires further study.</p></abstract><trans-abstract xml:lang="ru"><p><italic>Helicobacter pylori</italic> считается этиологическим агентом хронического гастрита и ряда других заболеваний желудочно-кишечного тракта. Иммунный ответ на <italic>H. pylori</italic> характеризуется развитием как провоспалительных, так и толерогенных реакций. На этом фоне предполагается также возможность формирования аутоиммунных сдвигов. Цель настоящей работы — проведение сравнительного анализа состояния иммунитета у больных хроническим гастритом в стадии обострения, ассоциированным и не ассоциированным с инфицированием <italic>H. pylori</italic>. В работе использовали образцы цельной периферической крови (n = 50) и плазмы крови (n = 49) больных с впервые выявленным хроническим гастритом в стадии обострения, у которых с помощью ПЦР в реальном времени в желудочном соке тестировалось наличие или отсутствие ДНК <italic>H. pylori</italic>. В периферической крови больных с помощью проточной цитофлуориметрии и моноклональных антител оценивали относительное содержание CD4<sup>+</sup>FoxP3<sup>+</sup> клеток (Т-регуляторы) и CD4<sup>+</sup>CD161<sup>+</sup> клеток (IL-17 продуцирующие клетки), с помощью ОТ-ПЦР в реальном времени определяли уровень мРНК FoxP3 и мРНК IL-17A, с применением иммуноферментного анализа определяли концентрацию IL-2 и IL-23. Показано, что у инфицированных <italic>H. pylori</italic> больных хроническим гастритом в стадии обострения, по сравнению с больными, не инфицированными <italic>H. pylori</italic>, в крови не изменяется содержание CD4<sup>+</sup>FoxP3<sup>+</sup> клеток, CD4<sup>+</sup>CD161<sup>+</sup> клеток, а также уровень мРНК FoxP3 и мРНК IL-17A. Поскольку равновесие между популяциями Тh17-клеток и Т-регуляторов модулируется IL-2, который важен для генерации популяции Т-регуляторов, но ингибирует поляризацию иммунного ответа в сторону Th17-клеток, мы провели сравнительную оценку содержания IL-2 в крови больных хроническим гастритом. У всех больных выявлено повышение содержания IL-2 в сравнении с нормой. При этом концентрация IL-2 в крови инфицированных <italic>H. pylori</italic> больных была статистически значимо выше, чем у больных, не инфицированных <italic>H. pylori</italic>. Важным регулятором функции Th17-клеток является также IL-23, индуцирующий дифференцировку наивных Т-лимфоцитов в Тh17-клетки, принимающие участие в воспалительных и аутоиммунных реакциях. В связи с этим мы провели определение уровня данного цитокина в крови больных хроническим гастритом. Выявлено многократное повышение концентрации IL-23 в сравнении с нормальным уровнем и более высокое содержание IL-23 у инфицированных <italic>H. pylori</italic> больных в сравнении с неинфицированными больными. На основании полученных данных можно заключить, что пoвышение концентрации IL-23 не исключает возможности формирования аутоиммунных сдвигов с его участием у лиц с хеликобактерной инфекцией, однако этот вопрос требует дальнейшего изучения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Helicobacter pylori</kwd><kwd>chronic gastritis</kwd><kwd>lymphocytes</kwd><kwd>flow cytofluorimetry</kwd><kwd>RT-PCR</kwd><kwd>mRNA</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>Helicobacter pylori</kwd><kwd>хронический гастрит</kwd><kwd>лимфоциты</kwd><kwd>проточная цитофлуориметрия</kwd><kwd>ОТ-ПЦР</kwd><kwd>мРНК</kwd></kwd-group><funding-group><funding-statement xml:lang="en">I.N. Blokhina Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology, Nizhny Novgorod, Russian Federation</funding-statement><funding-statement xml:lang="ru">ФБУН "Нижегородский научно-исследовательский институт эпидемиологии и микробиологии имени академика И.Н. Блохиной" Роспотребнадзора</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Матвеичев А.В., Талаева М.В., Талаев В.Ю., Неумоина Н.В., Перфилова К.М., Лапаев Д.Г., Мохонова Е.В., Цыганова М.И., Коптелова В.Н., Никитина З.И., Лапин В.А., Мелентьев Д.А. Влияние Helicobacter pylori на дифференцировку Т-регуляторных клеток // Анализ риска здоровью. 2017. № 1. С. 21–28. [Matveichev А.V., Talaeva М.V., Talaev V.Yu., Neumoina N.V., Perfilova K.M., Lapaev D.G., Mokhonova E.V., Tsyganova M.I., Koptelova V.N., Nikitina Z.I., Lapin V.A., Melentiev D.A. Influence exerted by Helicobacter pylori on regulatory T-cells differentiation. Analiz riska zdoroviyu = Health Risk Analysis, 2017, no. 1, pp. 21–28. (In Russ.)] doi: 10.21668/health.risk/2017.1.03.eng</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Синяков А.А., Cмирнова О.В., Каспаров Э.В. Показатели некоторых цитокинов у больных хроническим, хроническим атрофическим гастритом на фоне Helicobacter pylori-инфекции // Сибирский журнал естественных наук и сельского хозяйства. 2019. Т. 11, № 5–2. С. 124–128. [Sinyakov A.A., Smirnova O.V., Kasparov E.V. Indicators of some cytokines in patients with chronic, chronic atrophic gastritis with Helicobacter pylori infection. Sibirskiy zhurnal estestvennykh nauk i sel’skogo khozyaystva = Siberian Journal of Life Sciences and Agriculture, 2019, vol. 11, no. 5–2, pp. 124–128. (In Russ.)] doi: 10.12731/2658-6649-2019-11-5-2-124-128</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Цыганова М.И., Талаева М.В., Талаев В.Ю., Неумоина Н.В., Перфилова К.М., Мохонова E.B., Лапин В.А., Мелентьев Д.А. Влияние Helicobacter pylori на содержание провоспалительных Т-клеточных цитокинов и продуцирующих их субпопуляций // Анализ риска здоровью. 2018. № 3. С. 120–127. [Tsyganova M.I., Talaeva M.V., Talaev V.Yu., Neumoina N.V., Perfilova K.M., Mokhonova E.V., Lapin V.A., Melentiev D.A. Influence exerted by Helicobacter pylori on concentrations of anti-inflammatory T-cell cytokines and sunpopulations that produce them. Analiz riska zdorov’yu = Health Risk Analysis, 2018, no. 3, pp. 120–127. (In Russ.)] doi: 10.21668/health.risk/2018.3.13.eng</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Afzali B., Mitchell P.J., Edozie F.C., Povoleri G.A.M., Dowson S.E., Demandt L., Walter G., Canavan J.B., Scotta C., Menon B., Chana P.S., Khamri W., Kordasti S., Heck S., Grimbacher B., Tree T., Cope A.P., Taams L.S., Lechler R.I., John S., Lombardi G. CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. Eur. J. Immunol., 2013, vol. 43, no. 8, pp. 2043–2054. doi: 10.1002/eji.201243296</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Altobelli A., Bauer M., Velez K., Cover T.L., Müller A. Helicobacter pylori VacA targets myeloid cells in the gastric lamina propria to promote peripherally induced regulatory T-cell differentiation and persistent infection. mBio, 2019, vol. 10, no. 2: e00261-19. doi: 10.1128/mBio.00261-19</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Caruso R., Fina D., Paoluzi O.A., Blanco G.D.V., Stolfi C., Rizzo A., Caprioli F., Sarra M., Andrei F., Fantini M.C., MacDonald T.T., Pallone F., Monteleone G. IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur. J. Immunol., 2008, vol. 38, no. 2, pp. 470–478. doi: 10.1002/eji.200737635</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Caruso R., Pallone F., Monteleone G. Emerging role of IL-23/IL-17 axis in H. pylori-associated pathology. World J. Gastroenterol., 2007, vol. 13, no. 42, pp. 5547–5551. doi: 10.3748/wjg.v13.i42.5547</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Chmiela M., Gonciarz W. Molecular mimicry in Helicobacter pylori infections. World J. Gastroenterol., 2017, vol. 23, no. 22, pp. 3964–3977. doi: 10.3748/wjg.v23.i22.3964</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Chojnacki C., Popławski T., Błońska A., Błasiak J., Romanowski M., Chojnacki J. Expression of tryptophan hydroxylase in gastric mucosa in symptomatic and asymptomatic Helicobacter pylori infection. Arch. Med. Sci., 2019, vol. 15, no. 2, pp. 416–423. doi: 10.5114/aoms.2018.76928</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dixon B.R.E.A., Hossain R., Patel R.V., Algood H.M.C. Th17 Cells in Helicobacter pylori infection: a dichotomy of help and harm. Infect. Immun., 2019, vol. 87, no 11: e00363-19. doi: 10.1128/IAI.00363-19</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Dominguez-Andres J., Netea M.G. Impact of historic migrations and evolutionary processes on human immunity. Trends Immunol., 2019, vol. 40, no. 12, pp. 1105–1119. doi: 10.1016/j.it.2019.10.001</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>FitzGerald R., Smith S.M. An overview of Helicobacter pylori infection. Methods Mol. Biol., 2021, vol. 2283, pp 1–14. doi: 10.1007/978-1-0716-1302-3_1</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Hoeve M.A., Savage N.D.L., de Boer T., Langenberg D.M.L., de Waal Malefyt R., Ottenhoff T.H.M., Verreck F.A.W. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur. J. Immunol., 2006, vol. 36, no. 3, pp. 661–670. doi: 10.1002/eji.200535239</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hussain K., Letley D.P., Greenaway A.B., Kenefeck R., Winter J.A., Tomlinson W., Rhead J., Staples E., Kaneko K., Atherton J.C., Robinson K. Helicobacter pylori-mediated protection from allergy is associated with IL-10-secreting peripheral blood regulatory T cells. Front. Immunol., 2016, vol. 7: 71. doi: 10.3389/fimmu.2016.00071</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Jang T.J. The number of Foxp3-positive regulatory T-cells is increased in Helicobacter pylori gastritis and gastric cancer. Pathol. Res. Pract., 2010, vol. 206, no. 1, pp. 34–38. doi: 10.1016/j.prp.2009.07.019</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kandulski А., Malfertheiner Р., Wex Т. Role of regulatory T-cells in H. pylori-induced gastritis and gastric cancer. Anticancer Res., 2010, vol. 30, no. 4, pp. 1093–1103.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lankarani K.B., Honarvar B., Athari S.S. The mechanisms underlying Helicobacter pylori-mediated protection against allergic asthma. Tanaffos, 2017, vol. 16, no. 4, pp. 251–259.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Laurence A., Tato C. M., Davidson T.S., Kanno Y., Chen Z., Yao Z., Blank R.B., Meylan F., Siegel R., Hennighausen L., Shevach E.M., O'Shea J.J. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity, 2007, vol. 26, no. 3, pp. 371–381. doi: 10.1016/j.immuni.2007.02.009</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Leja M., Axon A., Brenner H. Epidemiology of Helicobacter pylori infection. Helicobacter, 2016, vol. 21, no. 1, pp. 3–7. doi: 10.1111/hel.12332</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Li L., He J., Zhu L., Yang J.Y., Jia R., Liu X., Liu Y., Sun X., Li Z. The clinical relevance of IL-17-producing CD4+ CD161+ cell and its subpopulations in primary Sjögren’s Syndrome. J. Immunol. Res., 2015: 307453. doi: 10.1155/2015/307453</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Magen E., Delgado J.-S. Helicobacter pylori and skin autoimmune diseases. World J. Gastroenterol., 2014, vol. 20, no. 6, pp. 1510–1516. doi: 10.3748/wjg.v20.i6.1510</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Maggi L., Santarlasci V., Capone M., Peired A., Frosali F., Crome S.Q., Querci V., Fambrini M., Liotta F., Levings M.K., Maggi E., Cosmi L., Romagnani S., Annunziato F. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur. J. Immunol., 2010, vol. 40, no. 8, pp. 2174–2181. doi: 10.1002/eji.200940257</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., Sedgwick J.D., Cua D.J. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med., 2003, vol. 198, no. 12, pp. 1951–1957. doi: 10.1084/jem.20030896</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Outlioua A., Badre W., Desterke C., Echarki Z., El Hammani N., Rabhi M., Riyad M., Karkouri M., Arnoult D., Khalil A., Akarid K. Gastric IL-1β, IL-8, and IL-17A expression in Moroccan patients infected with Helicobacter pylori may be a predictive signature of severe pathological stages. Cytokine, 2020, vol. 126: 154893. doi: 10.1016/j.cyto.2019.154893</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ramesh R., Kozhaya L., McKevitt K., Djuretic I.M., Carlson T.J., Quintero M.A., McCauley J.L., Abreu M.T., Unutmaz D., Sundrud M.S. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med., 2014, vol. 211, no. 1, pp. 89–104. doi: 10.1084/jem.20130301</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Schinocca C., Rizzo C., Fasano S., Grasso G., Barbera L.L., Ciccia F., Guggino G. Role of the IL-23/IL-17 pathway in rheumatic diseases: an overview. Front. Immunol., 2021, vol. 12: 637829. doi: 10.3389/fimmu.2021.637829</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Shen H., Goodall J.C., Gaston J.S.H. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum., 2009, vol. 60, no. 6, pp. 1647–1656. doi: 10.1002/art.24568</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Tanaka S., Nagashima H., Cruz M., Uchida T., Uotani T., Abreu J.A.J., Mahachai V., Vilaichone R., Ratanachuek T., Tshering L., Graham D.Y., Graham D.Y., Yamaoka Y. Interleukin-17C in human Helicobacter pylori gastritis. Infect. Immun., 2017, vol. 85, no. 10: e00389-17. doi: 10.1128/IAI.00389-17</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Wang S.K., Zhu H.F., He B.S., Zhang Z.Y., Chen Z.T., Wang Z.Z., Wu G.L. CagA+ H. pylori infection is associated with polarization of T helper cell immune responses in gastric carcinogenesis. World J. Gastroenterol., 2007, vol. 13, no. 21, pp. 2923–2931. doi: 10.3748/wjg.v13.i21.2923</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Zaky D.S.E., El-Nahrery E.M.A. Role of interleukin-23 as a biomarker in rheumatoid arthritis patients and its correlation with disease activity. Int. Immunopharmacol., 2016, vol. 31, pp. 105–108. doi: 10.1016/j.intimp.2015.12.011</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Zuo Z.T., Ma Y., Sun Y., Bai C.Q., Ling C.H., Yuan F.L. The protective effects of Helicobacter pylori infection on allergic asthma. Int. Arch. Allergy Immunol., 2021, vol. 182, no. 1, pp. 53–64. doi: 10.1159/000508330</mixed-citation></ref></ref-list></back></article>
